Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C

Table 2 Predictors of not achieving sustained virologic response in the overall sample identified using a multivariable regression model, n = 289

Variable	No SVR, n (%)	Crude OR, (95%CI)	Adjusted OR, (95%CI)	Adjusted P
Age (yr)
< 40	6 (7.1)	1	1
40-65	8 (4.5)	0.63 (0.21-1.87)	0.26 (0.67-0.99)	0.049
> 65	4 (14.3)	2.19 (0.57-8.42)	1.26 (0.23-6.96)	0.79
Sex
Female	8 (4.8)	1	1
Male	12 (7.4)	1.59 (0.58-4.36)	3.0 (0.87-10.37)	0.08
Co-morbidities
None	2 (2.2)	1	1
0ne to two	10 (6.8)	3.24 (0.69-15.12)	1.36 (0.22-8.38)	0.74
More than two	6 (11.3)	5.62 (1.09- 28.93)	3.63 (0.52-25.49)	0.19
USD cirrhosis
No	5 (2.5)	1	1
Yes	13 (14.9)	6.92 (2.39-20.10)	9.41 (2.47-35.84)	0.001
HCV genotype
1	10 (4.9)	1	1
3	6 (12.2)	2.69 (0.93-7.81)	3.56 (1.03-12.38)	0.044
4	2 (5.4)	1.10 (0.23-5.25)	0.69 (0.13-3.75)	0.67
DAC regimen
Generic	6 (4.3)	1	1
Brand	12 (8.1)	1.96 (0.71-5.36)	2.00 (0.57-7.04)	0.28
WBC (× 109/L)		1.04 (0.89-1.21)
Haemoglobin (g/dL)		1.14 (0.92-1.41)
Platelets (× 109/L)		1.00 (0.96-1.01)
PT (sec)		1.02 (0.95-1.05)
PTT (sec)		1.12 (0.98-1.29)
INR		0.99 (0.72-1.38)
Creatinine (μmol/L)		1.00 (0.98-1.01)
Albumin (g/L)		0.98 (0.90-1.06)
Total bilirubin (μmol/L)		0.99 (0.96-1.03)
ALP (U/L)		1.05 (0.99-1.02)
ALT (U/L)		1.01 (1.00-1.02)
gGT(U/L)		1.03 (1.00-1.06)

HCV: Hepatitis C virus; WBC: White blood cell count; USD: Ultrasound-diagnosed; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase; SVR: Sustained virologic response; 95%CI: 95% confidence interval; OR: Odds ratio.